SCM
XBIT icon

Sterling Capital Management’s XBiotech XBIT Stock Holding History

Sterling Capital Management’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-358
Closed -$1.16K – 3411
2025
Q1 		$1.16K Sell
358
-319
-47% -$1.1K ﹤0.01% 2766
2024
Q4 		$2.67K Buy
677
+618
+1,047% +$4.21K ﹤0.01% 2700
2024
Q3 		$456 Buy
+59
New +$388 ﹤0.01% 2915

Other funds holding XBIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sterling Capital Management's XBIT Position: Q2 2025 in Review

Sterling Capital Management sold out of XBiotech (XBIT) in Q2 2025, closing a stake of 358 shares — an estimated $1.16K sold.

Sterling Capital Management first reported a position in XBIT in Q3 2024 and held it in 3 quarters. The position peaked at $2.67K in Q4 2024. 53 funds tracked by Wall St. Rank hold XBIT as of Q2 2025.

  • Sterling Capital Management reported no remaining XBiotech position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 358 XBiotech shares in Q2 2025, an estimated $1.16K.
  • Sterling Capital Management first reported a position in XBiotech in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's XBiotech position peaked at $2.67K in Q4 2024.
  • 53 funds tracked by Wall St. Rank held XBiotech as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.